13.12 USD
▼-0.49-3.60%
盘后 13.59 +3.57%
2026-09-15
市值
$984.12M
市盈率
—
EPS
-4.05
股息率
—
52 周区间
3.76 – 14.35
成交量
1.20M
Beta
0.63
目标价
41.42
52W 低 3.7652W 高 14.35
价格走势
公司简介
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central ne...